Quality of Life and Late Effects Following Haploidentical Vs. Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Secondary Analysis of BMT CTN 1702
Key Points
Quality of life varies significantly between haploidentical transplantation and matched unrelated donor transplantation, revealing important disparities.
In a cohort from the BMT CTN 1702 trial, patients reported diverse late effects linked to their donor type, impacting their overall well-being.
Observational analysis across multiple centers explores the nuances of post-transplant experiences, highlighting crucial considerations for future protocols.
Impacts on physical and emotional quality of life suggest the need for tailored approaches in allogeneic transplantation, particularly concerning donor selection.
Quality of Life and Late Effects Following Haploidentical Vs. Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Secondary Analysis of BMT CTN 1702 | Synapse